Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 15/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | STAT5B | P51692 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PTPRS | Q13332 | 3/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601454 | 0.93 | RXRA (0.42) | MEN1KMT2AL3MBTL1CPB1STAT3 | |
| SCHEMBL5585312 | 0.92 | RXRA (0.41) | MEN1KMT2AL3MBTL1CPB1STAT3 | |
| SCHEMBL5585306 | 0.85 | CPB1 (0.38) | MEN1KMT2AL3MBTL1CPB1STAT3 | |
| SCHEMBL5585490 | 0.84 | KMT2A (0.41) | MEN1KMT2ACPB1STAT3USP30 | |
| SCHEMBL5585395 | 0.84 | ALDH1A1 (0.41) | MEN1KMT2AL3MBTL1CPB1USP30 | |
| SCHEMBL6000638 | 0.84 | RXRA (0.42) | MEN1KMT2AL3MBTL1CPB1STAT3 | |
| SCHEMBL5585392 | 0.84 | RXRA (0.42) | MEN1KMT2AL3MBTL1CPB1STAT3 | |
| Hydrochloric Acid SCHEMBL5585448 | 0.83 | RXRA (0.41) | MEN1KMT2AL3MBTL1CPB1STAT3 | |
| SCHEMBL5585241 | 0.83 | RXRA (0.41) | MEN1KMT2AL3MBTL1CPB1STAT3 | |
| SCHEMBL5585528 | 0.83 | RXRA (0.41) | MEN1KMT2AL3MBTL1CPB1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | MEN1 3299/4885KMT2A 2589/4885L3MBTL1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.